AU2003215524A1 - Pharmaceutical compositions comprising mannose binding lectin - Google Patents

Pharmaceutical compositions comprising mannose binding lectin

Info

Publication number
AU2003215524A1
AU2003215524A1 AU2003215524A AU2003215524A AU2003215524A1 AU 2003215524 A1 AU2003215524 A1 AU 2003215524A1 AU 2003215524 A AU2003215524 A AU 2003215524A AU 2003215524 A AU2003215524 A AU 2003215524A AU 2003215524 A1 AU2003215524 A1 AU 2003215524A1
Authority
AU
Australia
Prior art keywords
mbl
pharmaceutical compositions
binding lectin
compositions
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003215524A
Other languages
English (en)
Inventor
Leif Kongerslev
Jesper Lund Larsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NatImmune AS
Original Assignee
NatImmune AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NatImmune AS filed Critical NatImmune AS
Publication of AU2003215524A1 publication Critical patent/AU2003215524A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003215524A 2002-03-15 2003-03-14 Pharmaceutical compositions comprising mannose binding lectin Abandoned AU2003215524A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200414 2002-03-15
DKPA200200414 2002-03-15
PCT/DK2003/000179 WO2003077937A1 (en) 2002-03-15 2003-03-14 Pharmaceutical compositions comprising mannose binding lectin

Publications (1)

Publication Number Publication Date
AU2003215524A1 true AU2003215524A1 (en) 2003-09-29

Family

ID=27763313

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003215524A Abandoned AU2003215524A1 (en) 2002-03-15 2003-03-14 Pharmaceutical compositions comprising mannose binding lectin

Country Status (11)

Country Link
US (1) US7462596B2 (enExample)
EP (1) EP1344533B1 (enExample)
JP (1) JP2005526084A (enExample)
CN (1) CN1652813A (enExample)
AT (1) ATE337014T1 (enExample)
AU (1) AU2003215524A1 (enExample)
DE (1) DE60307701T2 (enExample)
DK (1) DK1344533T3 (enExample)
ES (1) ES2271515T3 (enExample)
PT (1) PT1344533E (enExample)
WO (1) WO2003077937A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002316811A1 (en) 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
CA2545034C (en) 2003-11-20 2013-03-05 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US7335633B2 (en) * 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
EP1618887A1 (en) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Clearance of polyols from the body
WO2006024631A2 (en) 2004-08-31 2006-03-09 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
KR101340354B1 (ko) 2004-11-12 2013-12-11 노보 노르디스크 에이/에스 안정한 펩티드 제제
WO2006071102A1 (en) * 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
US20080214435A1 (en) * 2005-04-11 2008-09-04 Natlmmune A/S Novel Cancer Indications of Mannan-Binding Lectin (Mbl) in the Treatment of Immunocompromised Individuals
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
US20090304686A1 (en) * 2006-03-08 2009-12-10 Universotair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen
CN105963289B (zh) 2007-09-10 2021-02-26 北京强新生物科技有限公司 一类stat3通路抑制剂和癌干细胞通路抑制剂
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
EP2454281B1 (en) 2009-07-17 2018-11-14 Omeros Corporation Masp isoforms as inhibitors of complement activation
JP5959440B2 (ja) 2010-01-19 2016-08-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 病原体の検出および治療のための改変オプソニン
RU2591823C2 (ru) 2010-03-19 2016-07-20 Бостон Байомедикал, Инк. Новые способы направленного воздействия на раковые стволовые клетки
EP2734843A2 (en) 2011-07-18 2014-05-28 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013130875A1 (en) 2012-02-29 2013-09-06 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
ES2864857T3 (es) * 2012-06-18 2021-10-14 Omeros Corp Composiciones y métodos para la inhibición de MASP-1 y/o MASP-2 y/o MASP-3 para el tratamiento de diversas enfermedades y trastornos
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
SG11201508358RA (en) 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
EP3010522B1 (en) 2013-05-21 2021-01-20 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
EP3912986B1 (en) 2013-12-18 2023-12-13 President and Fellows of Harvard College Crp capture/detection of bacteria
EP3331549B1 (en) 2015-08-06 2020-12-23 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
CN110755601B (zh) * 2019-10-31 2023-06-23 云南康洲生物科技有限公司 一种治疗hiv/aids免疫重建缺陷的芸豆凝集素植物药组合物和制备方法及其应用
US20230093542A1 (en) 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof
JP2024537924A (ja) * 2021-10-01 2024-10-16 インスティテュート オブ ケミストリー、テクノロジー アンド メタラジー サバリア・サバグリアの炭水化物結合ポリペプチド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2334696C (en) * 1998-06-10 2014-03-25 Statens Serum Institut Purification process for production of mannan-binding lectin and an mbl medicinal product
US6429192B1 (en) * 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
US6297024B1 (en) * 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
RU2292217C2 (ru) * 1999-05-14 2007-01-27 Стеффен ТИЭЛЬ Рекомбинантный маннан-связывающий лектин человека
US7211396B2 (en) * 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin

Also Published As

Publication number Publication date
DE60307701T2 (de) 2007-10-11
WO2003077937A1 (en) 2003-09-25
DK1344533T3 (da) 2007-01-08
ATE337014T1 (de) 2006-09-15
PT1344533E (pt) 2007-01-31
US7462596B2 (en) 2008-12-09
DE60307701D1 (de) 2006-10-05
JP2005526084A (ja) 2005-09-02
EP1344533B1 (en) 2006-08-23
US20040006009A1 (en) 2004-01-08
EP1344533A1 (en) 2003-09-17
ES2271515T3 (es) 2007-04-16
CN1652813A (zh) 2005-08-10

Similar Documents

Publication Publication Date Title
AU2003215524A1 (en) Pharmaceutical compositions comprising mannose binding lectin
CA2319308A1 (en) Pharmaceutical agents
HUP0401241A3 (en) Novel cyclohexyl sulphones, process for their preparation and pharmaceutical compositions containing them
HUP0303148A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing the compounds and processes for their preparation
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
CZ20012028A3 (cs) Nové N-substituované 2-kyanopyrrolidiny, farmaceutický prostředek, který je obsahuje a jejich použití jako léčivo
CA2534798A1 (en) Thiazole derivatives as cannabinoid receptor modulators
HUP0400246A3 (en) 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
CA2338600A1 (en) Novel thiazolopyrimidine compounds
HUP0103063A3 (en) Novel 2h-pyridazin-3-one derivatives, process for their preparation, their use and pharmaceutical compositions containing them
WO2000073452A3 (en) Compositions and methods for the treatment of immune related diseases
IL171914A0 (en) Variants of il-18bp, their preparation and pharmaceutical compositions containing them
AU2003202719A1 (en) Novel antibacterial compounds:process for their preparation and pharmaceutical compositions containing them.
CA2388910A1 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
AU2002348829A1 (en) Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO2003020963A3 (en) Proteins in type 2 diabetes
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
WO2003050067A3 (fr) Analogues de la vitamine d
HUP0401082A3 (en) Substituted 4-aminocyclohexanols, process for their preparation and pharmaceutical compositions containing them
WO2000072833A3 (de) Pharmazeutische zubereitungen zur hemmung von spimgomyelinase
WO2004031222A3 (en) Dna vaccine encoding at least two nonstructural early proteins of papillomavirus
HUP0401906A3 (en) Novel cathepsin s inhibitors, process for their preparation and pharmaceutical compositions containing them
CA2436537A1 (en) Pharmaceutical compositions comprising tiotropium salts and antihistamines

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase